The Delta G Avaris Approach: Personalized Phage Therapy for Broad Application
Delta G Avaris aims to be a full-service provider for personalized phage therapy, combining pathogen analysis, a comprehensive phage bank, and GMP-certified production.
Phage therapy is based on a principle discovered over 100 years ago and continues to evolve into a promising, highly targeted approach to combating bacterial infections. Our medical team has extensive experience in the use of phage therapy for patients with a wide variety of difficult-to-treat infections at Hannover Medical School (MHH), where promising results have been achieved. At Delta G Avaris, we aim to build on this expertise and advance it further while driving next-generation phage therapy technologies. We place particular emphasis on matching each phage specifically to the respective bacterial pathogen, enabling highly precise action while preserving the surrounding microbiome.
How Does Phage Therapy Work?
Phage therapy uses special viruses called bacteriophages that infect and destroy specific bacteria.
Unlike antibiotics, phages act only against the targeted pathogen, preserving the body's healthy microbiota. The WHO recognizes phages as a promising tool in the fight against antibiotic resistance; particularly against the so-called ESKAPE pathogens
What Are ESKAPE Pathogens?
ESKAPE pathogens represent six particularly dangerous bacterial species: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.
They are named for their ability to "escape" standard antibiotic treatments and are responsible for serious hospital-acquired infections. The WHO classifies them among the world's most critical health threats.
Delta G Avaris focuses initially on these pathogens, with a scalable approach adaptable to any bacterial target.
No escape for ESKAPE. We have these pathogens in our sights!
| Pathogen | Typical Infections |
|---|---|
| Enterococcus faecium | Urinary tract infections, endocarditis, sepsis |
| Staphylococcus aureus | Skin and soft tissue infections, pneumonia, osteomyelitis, sepsis |
| Klebsiella pneumoniae | Pneumonia, urinary tract infections, sepsis |
| Acinetobacter baumannii | Pneumonia, wound/catheter infections, sepsis |
| Pseudomonas aeruginosa | Pneumonia, urinary tract infections, wound infections, sepsis |
| Enterobacter spp. | Pneumonia, urinary tract infections, sepsis |
Side-effect-free alternative to antibiotics
100% tailored to the pathogen
Highly effective, even in severe and chronic cases
Side-effect-free alternative to antibiotics
100% tailored to the pathogen
Highly effective, even in severe and chronic cases
Three Approaches to Phage Therapy
There are different strategies for using bacteriophages therapeutically. The degree of individualization significantly determines efficacy.
Ready-Made Cocktails
Pre-formulated phage mixtures
Pre-made phage preparations with a fixed composition designed to target a broad range of pathogens.
Cocktails with 3–4 Phages
Tailored mixture
A mixture of several phages tailored to the specific pathogen, with higher effectiveness than ready-made cocktails.
Individualized Single Phages
Our ApproachPrecisely matched to the pathogen
Based on a phagogram, the single phage that combats the individual pathogen with maximum precision is identified.
The Analysis: Phagogram
In the case of an infection, the pathogen is first isolated and cultured. Potential candidates from our phage bank are then tested for their effectiveness in a process known as Phage Susceptibility Testing (PST). Based on this phagogram, we can determine with certainty which phage is best suited for the active substance.
Our Phage Discovery Collection
We are building a dynamic phage discovery collection designed to support the development of future precision therapies. This evolving library consists of phenotypically and genetically characterized bacteriophages and host bacteria, forming an important foundation for our long-term research ambitions. As the collection grows, we are advancing sophisticated analytical capabilities—including AI-supported methods—to explore how phage–pathogen matching could be optimized in future therapeutic applications.
GMP-Certified Manufacturing
Amplification
Cultivation of bacteriophages on the relevant bacterial strain.
Purification
Production of high-purity preparations suitable for oral, topical, inhalative, or intravenous use.
Quality Control
Continuous testing and certification according to the European Pharmacopoeia.
Formulation
Preparation for application in multiple forms as required.
Detailed Scientific Information
Further study data and professional documentation are exclusively available to healthcare professionals.